

**RESPONSE TO ELECTION OF
SPECIES REQUIREMENT
U.S. Appln. No. 09/674,377**

REMARKS

On page 1 of the Office Action, the Examiner indicates that Claims 1-24 are pending in the application. However, the Examiner is requested to note that, in fact, Claims 1-37 are pending in the application. Claims 1-18 were presented in the Article 34 amendment during the International phase and Claims 19-37 were added in the Preliminary Amendment filed May 29, 2002.

On page 2 of the Office Action, the Examiner issues a Election of Species Restriction Requirement to one of the following species:

- (a) rheumatoid arthritis,
- (b) psoriasis,
- (c) Osler-Webber syndrome,
- (d) myocardial angiopoiesis,
- (e) telangiectasia,
- (f) hemophilic joint,
- (g) angiogenic diseases of the eyes,
- (h) angiofibroma,
- (i) benign tumors,
- (j) wound granulation,
- (k) enteric adhesion,
- (l) Crohn's disease,
- (m) atherosclerosis,
- (n) scleroderma,
- (o) overcicatrization,
- (p) regulation of conception, or
- (q) cancer.

**RESPONSE TO ELECTION OF
SPECIES REQUIREMENT
U.S. Appln. No. 09/674,377**

Specifically, the Examiner states that the these species are deemed to be lacking unity of invention because they are not so linked as to form a single general inventive concept.

The Examiner notes that Claims 1-7, 9, 11-15 and 17-20 are generic.

The Examiner is also requested to note that since there are total of 37 claims pending in the application, there are additional generic claims which the Examiner is requested to acknowledge.

The Examiner notes that upon allowance of a generic claim, Applicants will be entitled to consideration of claims to additional species.


Accordingly, Applicants hereby elect the following species (q) cancer for examination purposes only, and request that the Examiner search additional species once she finds the elected species allowable. At least Claims 21-26 and 28-36, read on the elected species.

Applicants traverse the Examiner's Election of Species Requirement as the inventive concept of the present invention for all of the claims lie in the same active ingredient, and thus the claims are linked by a single general inventive concept.

**RESPONSE TO ELECTION OF
SPECIES REQUIREMENT
U.S. Appln. No. 09/674,377**

The Examiner is invited to contact the undersigned at the below-listed number on any questions which might arise.

Respectfully submitted,



Gordon Kit
Registration No. 30,764

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: November 4, 2005